Transactions
11
Insider / BridgeBio Pharma, Inc.
Apuli Maricel
Chief Accounting Officer at BridgeBio Pharma, Inc.
- Company
- BridgeBio Pharma, Inc.
- Ticker
- BBIO
- First filing on record
- November 18, 2025
- Latest trade on record
- August 16, 2026
- SEC filings
- EDGAR ↗
Apuli Maricel, Chief Accounting Officer at BridgeBio Pharma, Inc., has disclosed 11 transactions in BBIO since November 18, 2025: 0 purchases (0 open-market buys) and 10 sales, worth about $2.1M at the reported prices. The latest was filed August 18, 2026, 2 days after the trade.
Open-market buys
0
Sales
10
Avg. disclosure lag
2.5d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Apuli Maricel made no purchases and 10 sales worth $2.1M, plus 1 other transaction. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Apuli Maricel has traded 1 stock on record; the largest by dollars is BBIO.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 10 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| F | Shares withheld for tax | 5 | 20,561 | $1.5M |
| S | Open-market sale | 5 | 8,510 | $622K |
| A | Grant or award | 1 | 14,170 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 8 | 0 | 7 · $1.5M |
| 2025 | 3 | 0 | 3 · $616K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| BBIO | Sell F | August 16, 2026 | August 18, 2026 | 2d | 4,714 | $80 | $376K | Form 4 ↗ | ||
| BBIO | Sell S | July 30, 2026 | August 3, 2026 | 4d | 2,000 | $80 | $160K | 10b5-1 plan | Form 4 ↗ | |
| BBIO | Sell F | May 16, 2026 | May 19, 2026 | 3d | 4,714 | $66 | $312K | Form 4 ↗ | ||
| BBIO | Sell S | April 30, 2026 | May 4, 2026 | 4d | 2,000 | $72 | $143K | 10b5-1 plan | Form 4 ↗ | |
| BBIO | Other A | March 18, 2026 | March 20, 2026 | 2d | 14,170 | — | — | Form 4 ↗ | ||
| BBIO | Sell S | February 26, 2026 | February 27, 2026 | 1d | 2,000 | $66 | $132K | 10b5-1 plan | Form 4 ↗ | |
| BBIO | Sell S | February 17, 2026 | February 18, 2026 | 1d | 510 | $74 | $38K | 10b5-1 plan | Form 4 ↗ | |
| BBIO | Sell F | February 16, 2026 | February 18, 2026 | 2d | 4,349 | $75 | $327K | 10b5-1 plan | Form 4 ↗ | |
| BBIO | Sell F | December 12, 2025 | December 16, 2025 | 4d | 2,003 | $75 | $151K | Form 4 ↗ | ||
| BBIO | Sell S | December 8, 2025 | December 10, 2025 | 2d | 2,000 | $74 | $149K | 10b5-1 plan | Form 4 ↗ | |
| BBIO | Sell F | November 16, 2025 | November 18, 2025 | 2d | 4,781 | $66 | $317K | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| August 18, 2026 | Form 4 | 0001470831-26-000835 | 1 | published | EDGAR ↗ |
| August 3, 2026 | Form 4 | 0001470831-26-000745 | 1 | published | EDGAR ↗ |
| May 19, 2026 | Form 4 | 0001470831-26-000471 | 1 | published | EDGAR ↗ |
| May 4, 2026 | Form 4 | 0001470831-26-000410 | 1 | published | EDGAR ↗ |
| March 20, 2026 | Form 4 | 0001470831-26-000302 | 1 | published | EDGAR ↗ |
| February 27, 2026 | Form 4 | 0001470831-26-000225 | 1 | published | EDGAR ↗ |
| February 18, 2026 | Form 4 | 0001470831-26-000186 | 2 | published | EDGAR ↗ |
| December 16, 2025 | Form 4 | 0001470831-25-000418 | 1 | published | EDGAR ↗ |
| December 10, 2025 | Form 4 | 0001470831-25-000392 | 1 | published | EDGAR ↗ |
| November 18, 2025 | Form 4 | 0001470831-25-000349 | 1 | published | EDGAR ↗ |
Other insiders at BridgeBio Pharma, Inc.
- Kumar Neil Chief Executive Officer 158 rows
- Cook Jennifer E. Director 22 rows
- Valantine Hannah Director 16 rows
- Scott Randal W. Director 15 rows
- MOMTAZEE JAMES C Director 12 rows
- Trimarchi Thomas President and CFO 12 rows
- MCCORMICK FRANK Director 9 rows
- Dachille Douglas A. Director 8 rows
- Ellis Andrea Director 8 rows
- Lo Andrew Director 6 rows
Everyone on file, with contracts and lobbying under the company's name: BridgeBio Pharma, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 10 | 11 | November 18, 2025 | August 18, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.